S&P 500   4,145.19
DOW   32,803.47
QQQ   322.92
What to Expect from the Markets in a Recession
Sell every Stock except ONE (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Biden's Plan to Confiscate Your Cash? (Ad)
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
Dems push Biden climate, health priorities toward Senate OK
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.92
What to Expect from the Markets in a Recession
Sell every Stock except ONE (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Biden's Plan to Confiscate Your Cash? (Ad)
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
Dems push Biden climate, health priorities toward Senate OK
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.92
What to Expect from the Markets in a Recession
Sell every Stock except ONE (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Biden's Plan to Confiscate Your Cash? (Ad)
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
Dems push Biden climate, health priorities toward Senate OK
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,145.19
DOW   32,803.47
QQQ   322.92
What to Expect from the Markets in a Recession
Sell every Stock except ONE (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Biden's Plan to Confiscate Your Cash? (Ad)
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
Dems push Biden climate, health priorities toward Senate OK
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NYSE:RCUS

Arcus Biosciences - RCUS Stock Forecast, Price & News

$27.33
+0.48 (+1.79%)
(As of 08/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$26.01
$27.57
50-Day Range
$18.95
$30.07
52-Week Range
$16.74
$49.10
Volume
29,960 shs
Average Volume
985,585 shs
Market Capitalization
$1.96 billion
P/E Ratio
38.49
Dividend Yield
N/A
Price Target
$48.75

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
78.4% Upside
$48.75 Price Target
Short Interest
Bearish
16.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.26mentions of Arcus Biosciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$291,220 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.06) to ($4.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

575th out of 1,293 stocks

Pharmaceutical Preparations Industry

270th out of 619 stocks

RCUS stock logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Analyst Upgrades and Downgrades

RCUS has been the topic of several recent analyst reports. SVB Leerink dropped their target price on Arcus Biosciences from $66.00 to $49.00 and set an "outperform" rating on the stock in a report on Thursday. Truist Financial lowered their target price on Arcus Biosciences from $77.00 to $50.00 and set a "buy" rating on the stock in a report on Friday, July 8th. Wedbush cut their price target on Arcus Biosciences from $42.00 to $36.00 and set an "outperform" rating for the company in a report on Thursday. Finally, Cantor Fitzgerald decreased their price objective on Arcus Biosciences from $62.00 to $48.00 in a report on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $48.75.

Arcus Biosciences Trading Up 1.8 %

Shares of Arcus Biosciences stock opened at $27.33 on Monday. Arcus Biosciences has a twelve month low of $16.74 and a twelve month high of $49.10. The stock has a market capitalization of $1.96 billion, a P/E ratio of 38.49 and a beta of 0.71. The business's fifty day moving average price is $25.11 and its 200 day moving average price is $27.95.

Arcus Biosciences (NYSE:RCUS - Get Rating) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.93) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.93). Arcus Biosciences had a return on equity of 9.12% and a net margin of 16.34%. The firm had revenue of $26.76 million for the quarter, compared to analysts' expectations of $21.00 million. During the same quarter last year, the firm earned ($1.09) earnings per share. As a group, sell-side analysts predict that Arcus Biosciences will post -4.06 EPS for the current year.

Insiders Place Their Bets

In other Arcus Biosciences news, CEO Terry J. Rosen sold 4,241 shares of the business's stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total transaction of $87,873.52. Following the transaction, the chief executive officer now owns 232,329 shares in the company, valued at $4,813,856.88. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Terry J. Rosen sold 4,241 shares of Arcus Biosciences stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total transaction of $87,873.52. Following the sale, the chief executive officer now directly owns 232,329 shares of the company's stock, valued at $4,813,856.88. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Juan C. Jaen sold 2,333 shares of Arcus Biosciences stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total value of $48,339.76. Following the sale, the president now directly owns 212,574 shares in the company, valued at $4,404,533.28. The disclosure for this sale can be found here. Insiders have sold a total of 14,055 shares of company stock worth $291,220 over the last quarter. 12.70% of the stock is owned by corporate insiders.

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

Arcus Biosciences (NYSE:RCUS) PT Lowered to $36.00 at Wedbush
Arcus Biosciences (NYSE:RCUS) Trading 7.7% Higher
Why Precision BioSciences Shares Are Surging Today
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Company Calendar

Last Earnings
8/03/2022
Today
8/08/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
366
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.75
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+78.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$52.83 million
Pretax Margin
17.02%

Debt

Sales & Book Value

Annual Sales
$382.88 million
Cash Flow
$0.87 per share
Book Value
$11.98 per share

Miscellaneous

Free Float
62,996,000
Market Cap
$1.96 billion
Optionable
Optionable
Beta
0.71














RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2022?

7 analysts have issued 1-year target prices for Arcus Biosciences' stock. Their RCUS stock forecasts range from $36.00 to $60.00. On average, they predict Arcus Biosciences' stock price to reach $48.75 in the next year. This suggests a possible upside of 78.4% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

How has Arcus Biosciences' stock performed in 2022?

Arcus Biosciences' stock was trading at $40.47 on January 1st, 2022. Since then, RCUS stock has decreased by 32.5% and is now trading at $27.33.
View the best growth stocks for 2022 here
.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our earnings forecast for Arcus Biosciences
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) issued its earnings results on Wednesday, August, 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.93). The company had revenue of $26.76 million for the quarter, compared to analyst estimates of $21 million. Arcus Biosciences had a net margin of 16.34% and a trailing twelve-month return on equity of 9.12%. During the same period last year, the company posted ($1.09) earnings per share.

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.10%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%), SG Americas Securities LLC (0.05%), State of Alaska Department of Revenue (0.05%) and Strs Ohio (0.05%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $27.33.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.96 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.71 on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 366 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for Arcus Biosciences is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.